From a Georgia steel plant rally, President Donald Trump disclosed wielding the tariff axe against French luxury exports to tame global drug prices. His 100% tariff warning on wine and champagne to President Emmanuel Macron yielded quick results, per Trump’s account.
Trump’s blueprint: peg American drug costs to the planet’s lowest available. He lambasted the status quo where U.S. buyers overpay massively—sometimes 13 times the rate abroad—prompting urgent calls to world leaders.
Macron initially balked during their chat, citing ruinous business impacts. Trump’s retort was unyielding: adjust prices, or every bottle of your wine hits American shelves with double duties. Macron relented promptly, pledging enthusiastic cooperation.
Echoing wins with Germany, Spain, and more, Trump hailed tariffs as negotiation gold. ‘My dictionary favorite—tariffs rebuilt our factories,’ he declared to cheering workers. He wove drug victories into his tariff tapestry, holding fire on some levies for court review.
Bragging rights include $18 trillion in 11-month investments and election-topping market peaks. Macron’s saga exemplifies Trump’s seamless weave of commerce, health policy, and international arm-twisting—with echoes sure to resound.
Chronic gripes target America’s premium pill prices against developed-world norms. Benchmark pushes ignite clashes; drugmakers decry threats to breakthroughs and supply logistics. Trump’s flair redefines the fight.